Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Core Viewpoint - Longeveron Inc. is set to report its first quarter 2025 financial results and provide a business update on May 8, 2025, after U.S. market close, followed by a conference call and webcast [1] Company Overview - Longeveron Inc. is a clinical stage biotechnology company focused on developing regenerative medicines to meet unmet medical needs [3] - The company's lead investigational product is laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell therapy derived from the bone marrow of young, healthy adult donors [3] - Laromestrocel has multiple potential mechanisms of action, including pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair effects, with applications across various disease areas [3] Pipeline and FDA Designations - Longeveron is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer's disease (AD), and aging-related frailty [3] - The HLHS program has received three FDA designations: Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation [3] - The AD program has received two important FDA designations: Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation [3]